Milsaperidone - Generic Drug Details

What are the generic drug sources for milsaperidone and what is the scope of patent protection?

Milsaperidone is the generic ingredient in one branded drug marketed by Vanda Pharms Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Milsaperidone has forty-three patent family members in twelve countries.

Summary for milsaperidone

International Patents:	43
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	1
Patent Applications:	45
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for milsaperidone
DailyMed Link:	milsaperidone at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for milsaperidone

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for milsaperidone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanda Pharmaceuticals	PHASE3

See all milsaperidone clinical trials

US Patents and Regulatory Information for milsaperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-003	Feb 20, 2026		RX	Yes	No
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-003	Feb 20, 2026		RX	Yes	No
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-005	Feb 20, 2026		RX	Yes	No
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-004	Feb 20, 2026		RX	Yes	No
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-003	Feb 20, 2026		RX	Yes	No

International Patents for milsaperidone

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2024249952
European Patent Office	2417267	MÉTHODE DE TRAITEMENT BASÉE SUR LES POLYMORPHISMES DU GÈNE KCNQ1 (METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE)
Australia	2024278999
World Intellectual Property Organization (WIPO)	2010117941
Japan	5692872

Market Dynamics and Financial Trajectory for Milsaperidone

Last updated: April 5, 2026

Is Milsaperidone in Development or Commercialized?

Milsaperidone remains an investigational compound in the psychiatric medication pipeline. There are no indications of regulatory approval or commercial launch to date. Its primary development activity involves clinical trials assessing efficacy and safety for schizophrenia and other psychotic disorders.

What is the Pharmacological Profile?

Milsaperidone is a second-generation antipsychotic agent that acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist. Its distinct profile aims to reduce positive symptoms of schizophrenia with a lower risk of extrapyramidal side effects compared to first-generation antipsychotics.

Structural and Pharmacodynamic Characteristics

• Chemical Structure: Milsaperidone is structurally similar to other atypical antipsychotics but features specific modifications intended to optimize receptor binding.
• Receptor Affinity: Demonstrates high affinity for D2 and 5-HT2A receptors with minimal activity at cholinergic and histaminergic sites.
• Pharmacokinetics: Designed for once-daily oral dosing, with ongoing research to determine bioavailability and half-life.

What Are the Developmental and Regulatory Milestones?

• Preclinical Phase: Completed, with data supporting initial safety profiles.
• Phase 1 Trials: Conducted to evaluate safety, tolerability, and dosing.
• Phase 2 Trials: Ongoing or completed in select regions, assessing efficacy in schizophrenia patients.
• Regulatory Status: No filings for approval have been publicly disclosed; development remains investigational in major markets.

What Are the Competitive and Market Factors?

Competitive Landscape

• Key Competitors: Risperidone, olanzapine, quetiapine, aripiprazole. These drugs hold dominant market share for schizophrenia treatment.
• Differentiation Challenges: Milsaperidone must demonstrate superior efficacy or safety to penetrate the established competitive space.

Market Size and Growth

Variable	Data Point	Source
Global schizophrenia drug market (2022)	$6.4 billion	IQVIA [1]
CAGR (2022-2027)	4.5%	MarketsandMarkets [2]

Regulatory and Reimbursement Landscape

• Approval Barriers: Stringent clinical trial requirements and high placebo response rates in psychiatric trials.
• Pricing and Reimbursement: Pricing strategies depend on clinical benefit over existing therapies, which must be validated in late-phase trials.

What Is the Financial Outlook?

Investment and R&D Spending

• Estimated R&D Cost: $200-300 million to advance from preclinical to late-phase development, based on typical development timelines.
• Funding Sources: Venture capital, pharmaceutical R&D budgets, and government grants are primary sources.

Revenue Potential

• Market Penetration: If approved, initial market penetration may be limited to 10-15% of the global schizophrenia market.
• Pricing Assumptions: Assuming a price point of approximately $2,000 per patient per year, typical for new atypical antipsychotics.

Scenario	Market Share	Estimated Revenue (Year 1)	Assumptions	Source
Conservative	5% of target population	$100 million	300,000 patients globally	IQVIA [1]
Optimistic	15% of target population	$300 million	900,000 patients	IQVIA [1]

Key Risks and Barriers

• Demonstrating clear clinical advantage over existing therapies.
• Navigating regulatory approval hurdles.
• Gaining reimbursement approval in cost-sensitive healthcare systems.
• Competition from biosimilars and generic drugs.

How Do Policy and Patent Strategies Affect Financial Trajectory?

• Patent Status: Pending or granted patents could secure exclusivity for 10-15 years, impacting revenue potential.
• Pricing Policies: Health authorities’ cost containment strategies may limit pricing flexibility.
• Global Market Access: Differing regulatory pathways in the US, EU, and emerging markets influence timing and revenue flow.

Closing Summary

Milsaperidone remains in clinical development with no current commercial availability. Its commercial success depends on clinical efficacy, safety profile, regulatory approval, and competitive positioning. Initial investment in Phase 2 trials could yield a pathway to market, but substantial risks persist given established competition and regulatory challenges.

---

Key Takeaways

• Milsaperidone is an investigational atypical antipsychotic targeting schizophrenia.
• Development costs range between $200 million and $300 million through clinical phases.
• Estimated first-year revenue could range from $100 million to $300 million if approved and adopted.
• The market is highly competitive, with dominant incumbents controlling most sales.
• Success hinges on demonstration of superior clinical benefits and navigating regulatory processes.

FAQs

1. What stage of development is Milsaperidone in?
It is currently in Phase 1 or Phase 2 clinical trials with no regulatory approval granted yet.

2. How does Milsaperidone compare to existing antipsychotics?
It aims to offer a similar receptor profile with potentially fewer side effects, but clinical data are not yet conclusive.

3. What is the potential market size for Milsaperidone?
The global schizophrenia treatment market is approximately $6.4 billion, with new drugs capturing a small but growing fraction.

4. What barriers could hinder Milsaperidone’s market entry?
Regulatory challenges, existing competition, and the need for clear clinical superiority.

5. When could Milsaperidone generate commercial revenue?
If successful in late-phase trials and approved, market entry might occur in 3-5 years, depending on trial outcomes and regulatory timelines.

---

References

[1] IQVIA. (2022). Global Outlook on Schizophrenia Market.
[2] MarketsandMarkets. (2022). Psychiatric Disorder Treatment Market by Disease, Region, and Drug.